Evidence map›Paper›PMID 38695107›Full record

Trial reportJournal of the International AIDS Society2024

Urine tenofovir testing for real-time PrEP adherence feedback: a qualitative study involving transgender women in Uganda.

Andrew Mujugira, Beyonce Karungi, Jackson Mugisha, Agnes Nakyanzi, Olivia Nampewo, Faith Naddunga, Brenda Kamusiime, Rogers Nsubuga, Kikulwe R Nyanzi, Timothy R Muwonge and 4 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of the International AIDS Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04328025 (Peer-Delivered HIV Self-Testing, STI Self-Sampling and PrEP for Transgender Women in Uganda), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04328025 naunknown statusnot on this map

Peer-Delivered HIV Self-Testing, STI Self-Sampling and PrEP for Transgender Women in Uganda

TypeinterventionalSponsorMakerere UniversityRan2020 to 2022Enrolled82ConditionsHIV, Sexually Transmitted Infections, PrEP, Transgender WomenArmsPeer-delivered HIV self-testing, STI self-sampling and PrEP
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Andrew MujugiraThe Infectious Diseases Institute Limited, Makerere University, Kampala, Uganda.ORCID 0000-0001-6646-6733
Beyonce KarungiTransgender Equality Uganda, Kampala, Uganda.
Jackson MugishaThe Infectious Diseases Institute Limited, Makerere University, Kampala, Uganda.
Agnes NakyanziThe Infectious Diseases Institute Limited, Makerere University, Kampala, Uganda.
Olivia NampewoThe Infectious Diseases Institute Limited, Makerere University, Kampala, Uganda.
Faith NaddungaThe Infectious Diseases Institute Limited, Makerere University, Kampala, Uganda.
Brenda KamusiimeThe Infectious Diseases Institute Limited, Makerere University, Kampala, Uganda.
Rogers NsubugaThe Infectious Diseases Institute Limited, Makerere University, Kampala, Uganda.
Kikulwe R NyanziThe Infectious Diseases Institute Limited, Makerere University, Kampala, Uganda.
Timothy R MuwongeThe Infectious Diseases Institute Limited, Makerere University, Kampala, Uganda.
Monique A WyattDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Norma C WareDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-5039-9991
Monica GandhiDepartment of Medicine, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0002-7025-1994
Jessica E HabererHarvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0001-5845-3190
Infectious Diseases Institute · UGHarvard University · USBrigham and Women's Hospital · USUniversity of California, San Francisco · USUniversity of Washington · US

Funding

Randomized Trial to Optimize Virologic Suppression Rates Using a Point-of-Care Urine Monitoring Assay (ROVING-PUMA)R01AI143340 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 2018 to 2026
$5.6M
Optimizing mHealth for adherence monitoring and interventionK24MH114732 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI HABERER, JESSICA ELIZABETH · 2017 to 2021
$800k
Transgender Men and HIV in Uganda: PrEP Uptake and PersistenceR34MH121084 · NIMH · INFECTIOUS DISEASES INSTITUTE · PI MUJUGIRA, ANDREW · 2019 to 2021
$584k
NIAID NIH HHS R01 AI143340NIMH NIH HHS K24 MH114732NIMH NIH HHS R34 MH121084
6 · The paper itself

Abstract

introductionAdherence counselling with point-of-care (POC) drug-level feedback using a novel tenofovir assay may support pre-exposure prophylaxis (PrEP) adherence; however, perceptions of urine testing and its impact on adherence are not well studied. We qualitatively examined how POC tenofovir testing was experienced by transgender women (TGW) in Uganda.

methodsWithin a cluster randomized trial of peer-delivered HIV self-testing, self-sampling for sexually transmitted infections and PrEP among HIV-negative TGW showing overall low PrEP prevention-effective adherence (NCT04328025), we conducted a nested qualitative sub-study of the urine POC assay among a random sample of 30 TGW (August 2021-February 2022). TGW interviews explored: (1) experiences with POC urine tenofovir testing and (2) perceptions of PrEP adherence counselling with drug-level feedback. We used an inductive content analytic approach for analysis.

resultsMedian age was 21 years (interquartile range 20-24), and 70% engaged in sex work. Four content categories describe how TGW experienced POC urine tenofovir testing: (1) Urine tenofovir testing was initially met with scepticism: Testing urine to detect PrEP initially induced anxiety, with some perceptions of being intrusive and unwarranted. With counselling, however, participants found POC testing acceptable and beneficial. (2) Alignment of urine test results and adherence behaviours: Drug-level feedback aligned with what TGW knew about their adherence. Concurrence between pill taking and tenofovir detection in urine reinforced confidence in test accuracy. (3) Interpretation of urine tenofovir results: TGW familiar with the interpretation of oral-fluid HIV self-tests knew that two lines on the test device signified positivity (presence of HIV). However, two lines on the urine test strip indicated a positive result for non-adherence (absence of tenofovir), causing confusion. Research nurses explained the difference in test interpretation to participants' satisfaction. (4) White coat dosing: Some TGW deliberately chose not to attend scheduled clinic appointments to avoid detecting their PrEP non-adherence during urine testing. They restarted PrEP before returning to clinic, a behaviour called "white coat dosing."

conclusionsIncorporating POC urine testing into routine PrEP adherence counselling was acceptable and potentially beneficial for TGW but required attention to context. Additional research is needed to identify effective strategies for optimizing adherence monitoring and counselling for this population.

Indexed as

Anti-HIV AgentsHIV InfectionsMedication AdherencePre-Exposure ProphylaxisTenofovirTransgender PersonsAdultCounselingFemaleHumansMaleQualitative ResearchUgandaYoung AdultAnti-HIV AgentsTenofoviradherenceAfricapre‐exposure prophylaxisqualitativetransgender womenurine tenofovir test

Identifiers

PMID38695107
PMCPMC11063774
OpenAlexW4396598157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.